Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026
Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026
Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Fineline Cube Jan 26, 2026
Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Fineline Cube Jan 26, 2026
Company Drug

Sanofi’s Sarclisa Receives CHMP Recommendation for Newly Diagnosed Multiple Myeloma

Fineline Cube Nov 15, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that the Committee for Medicinal Products for...

Company Deals Medical Device

J&J MedTech Secures Exclusive Distribution Deal with Responsive Arthroscopy

Fineline Cube Nov 15, 2024

Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading player in the US medical technology...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for SHR-2173 Clinical Trial in ITP

Fineline Cube Nov 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Drug

Eisai and Biogen’s Lecanemab Receives Positive CHMP Opinion for Early Alzheimer’s Treatment

Fineline Cube Nov 15, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced that the...

Policy / Regulatory

Merck Secures Exclusive Rights to LaNova’s PD-1/VEGF Bispecific Antibody LM-299

Fineline Cube Nov 15, 2024

US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced a significant...

Policy / Regulatory

China Releases Comprehensive AI Application Guidelines for Healthcare Industry

Fineline Cube Nov 15, 2024

The National Health Commission, National Administration of Traditional Chinese Medicine, and National Bureau of Disease...

Company

BeiGene Ltd to Become BeOne Medicines Ltd, Emphasizing Global Oncology Commitment

Fineline Cube Nov 15, 2024

China-based biotechnology company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a proposed...

Company Deals

Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China

Fineline Cube Nov 15, 2024

Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its...

Policy / Regulatory

NMPA Issues Interim Provisions for Overseas MAHs’ Designated Domestic Responsible Persons

Fineline Cube Nov 15, 2024

The National Medical Products Administration (NMPA) has released the “Interim Provisions on the Management of...

Company Drug

Sino Biopharmaceutical’s TQB3002 Receives FDA Clearance for Phase I Study

Fineline Cube Nov 15, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based pharmaceutical company, has announced that it has...

Company Deals

PegBio Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 15, 2024

PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant...

Company Drug

Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials

Fineline Cube Nov 15, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Drug

WuXi Biologics Expands Sterile Filling Capabilities in Germany with New Line

Fineline Cube Nov 15, 2024

China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans...

Company Drug

Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance

Fineline Cube Nov 15, 2024

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance...

Company Drug

Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC

Fineline Cube Nov 15, 2024

Singapore-based clinical-stage biotechnology company Lion TCR, supported by Chinese investors, has secured tacit clinical approval...

Company

BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care

Fineline Cube Nov 15, 2024

BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading global innovator in oncology treatments,...

Company Drug

Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study

Fineline Cube Nov 14, 2024

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...

Company Medical Device

GE Healthcare’s SIGNA MAGNUS MRI Scanner Receives FDA 510(k) Clearance

Fineline Cube Nov 14, 2024

US medical device and life sciences leader GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals

Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company

Fineline Cube Nov 14, 2024

Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is...

Company Drug

ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer

Fineline Cube Nov 14, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...

Posts pagination

1 … 214 215 216 … 613

Recent updates

  • Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets
  • Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
  • Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study
  • Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing
  • HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Company Drug

Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.